|TPG Growth Invests $75 Million in Precision for Medicine|
Leader in healthcare investing acquires stake in growing pharmaceutical services company
Fort Worth, Texas, San Francisco and Bethesda, MD — December 22, 2015 — TPG Growth, the middle market and growth equity investment platform of TPG, a leading global private investment firm with approximately $70 billion of assets under management, today announced a $75 million investment in Precision for Medicine, Inc. Additional details of the transaction were not disclosed.
Precision for Medicine is a specialty services company that supports pharmaceutical and life sciences companies through development and commercialization. The Company helps its clients develop products, demonstrate economic value, validate outcomes and build differentiation within the healthcare marketplace. For TPG, Precision for Medicine marks the Firm’s latest addition to a growing list of investments in some of the healthcare industry’s most innovative companies.
“TPG Growth leverages unparalleled healthcare expertise from across the TPG platform to identify companies that have exceptional opportunities for growth,” said Matthew Hobart, Partner at TPG Growth. “Precision for Medicine operates at the intersection of two of the fastest-growing areas in healthcare — precision medicine and value-based care. With a strong founding team and rapid organic and inorganic growth, the Company is well-positioned to capitalize on the advances inherent in leveraging clinical, genomic and molecular data to optimize medical treatment.”
“TPG’s industry insights and extraordinary track record of partnering with leading healthcare companies make them an ideal partner for us,” said Ethan Leder, Co-Founder and Executive Chairman of Precision for Medicine. “The life sciences market is experiencing unprecedented change and growth spurred by the innovations of precision medicine. At the same time, our clients’ innovations have to be rationalized in a market facing limited resources and demanding proof of value. We feel fortunate to be working with a team who understands our vision and has the resources and capabilities to support our growth. We look forward to working closely with TPG to continue our expansion.”
The investment builds upon TPG’s strong track record of investing in and partnering with some of the most transformative companies in the healthcare industry. Examples of such investments across TPG and TPG Growth include Access Clinical Partners / GoHealth Urgent Care, EnvisionRx, Evolent Health, IMS Health, NorthStar Anesthesia, Par Pharmaceutical, Quintiles, and Surgical Care Affiliates. Additionally, TPG Biotech has been one of the earliest and most active investors in personalized medicine and diagnostics, having invested in companies such as Genomic Health, Verracyte, and CareDx.
About TPG Growth
TPG Growth is the middle market and growth equity investment platform of TPG, the global private investment firm. With over $7 billion under management, TPG Growth targets investments in a broad range of industries and geographies. TPG Growth has the deep sector knowledge, operational resources and global experience to drive value creation and help companies reach their full potential. The firm is backed by the resources of TPG, which has approximately $70 billion of assets under management. TPG Growth's current and past investments represent a mix of iconic and innovative companies across tech, retail and entertainment including Uber, Airbnb, e.l.f. Cosmetics, Angie's Artisan Treats, Fender, SurveyMonkey, and Red Book Connect. TPG Growth has offices in the United States, China, India, Turkey, London and Singapore. For more information visit www.tpggrowth.com.
About Precision For Medicine